Dr. Tricot and I didn't restrict our conversation to the "transplant again or not" debate. We also spent a good deal of time discussing how to handle my worrisome peripheral neuropathy (PN). As I shared last month: Peripheral neuropathy smacks me hard! Thalidomide maintenance has sped up the progression of my PN exponentially. Fortunately,
I have expressed concern about the high cost of chemotherapy meds for me and my fellow multiple myeloma patients a number of times. So last night's 60 Minutes report about it really hit home. Here is an excerpt of the transcript that hits closest to home, featuring M.D. Anderson oncologist, Dr. Hagop Kantarjian discussing Gleevec,
An impressive website, NaturalNews.com, just published an article about turmeric's (curcumin) ability to destroy myeloma cells when combined with thalidomide. I first wrote about this project back in July: Could synthesizing and combining anti-myeloma drugs make them more effective? NaturalNews.com staff writer, Ethan Huff, looks at things from a different angle. Very interesting! Allow
Before I get started this morning, I wanted to share some sage advice that I received from one of my regular readers after they learned I was struggling with my father's life nearing the end: My father died suddenly a few weeks before his 39th birthday. I was eighteen at the time, my sister 11.
This is complicated stuff. But apparently a group of scientists have successfully synthesized thalidomide and curcumin. Taking things a step farther, researchers Kai Liu, Datong Zhang, Jeremy Chojnacki, Yuhong Du, Haian Fu, Steven Grant and Shijun Zhang have also been able to combine thalidomide and curcumin together, forming a compound that is exceptionally lethal to
I stuck with the original heading for the third installment of my three part investigative expose'. But today's post could have been titled, "Different shades of grey." Pomalidomide's development was shaped by a convoluted system that does a poor job balancing patient need with investor returns. But I'm getting ahead of myself. Yesterday I promised
Before I get started, did you happen to see the MMRF's Kathy Giusti interviewed in the trendy tech magazine, Fast Company? Interesting approach. Simply click-on the headline link below to access the interview: Using Data To Treat Cancer And Drive Innovation How a pair of savvy renegades are forcing collaboration in cancer R&D--and saving lives.
Most of you probably know that I have been working on several new books about multiple myeloma. My third book, New Myeloma Therapies from a Patient's Perspective, will be published and available by the end of this month. Researching this book reminded me about how difficult it can be to understand "myeloma research speak." It
Yesterday I set the stage for today’s report about research data which was featured at the International Myeloma Foundation’s Journalist Workshop Monday night. My original intention was to share a lot of specific data and facts--nothing but the facts. I plan to do just that--except for the “nothing but the facts” part. Because I think
Do you hate taking dexamethasone or prednisone? This new therapy combination of Velcade, pegylated liposomal doxorubicin (D), and thalidomide (T), may provide an an alternative option. Here is an abstract from a Phase 2 trial featuring the VDT combination: Abstract Novel agents have provided a new foundation for multiple myeloma therapies. When combined with other
I saved the link to this interesting article about the history of thalidomide, I found a few months back on a mainstream site called SLATE. Here are some selected excerpts from the article, along with a link to access the full text:Thalidomide's ComebackWho'd have thought the drug would have a second life?By Amanda SchafferA chemical
The Myeloma Beacon just broke the story about how the FDA is investigating Revlimid and Thalomid, based on research data showing a possible secondary cancer risk following long term, post transplant use. Here is an independent look at the pending investigation by Internal Medical News. I have highlighted key points I feel are important: FDA Keeping an
Excellent Article About Geraldine Ferraro’s Legacy And Ongoing Battle To Help Control Cost Of Cancer Meds…
Read this detailed recap/tribute to Geraldine Ferraro by Ann Law for Bizmology.com:Geraldine Ferraro leaves cancer research, health reform legacyMarch 28th, 2011A symbol of progress for women in US politics, former Congresswoman Geraldine Ferraro died Saturday at the age of 75. Her death, caused by complications from blood cancer multiple myeloma, not only reminds the nation
According to a new Czech study, posted earlier this month on Pub Med.gov, it doesn't matter whether you pick thalidomide (Thalomid) or bortezomib (Velcade) for treatment following first relapse. Apparently both work about one half of the time.Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.Krejci M, Gregora E, Straub J,
Multiple myeloma news runs in cycles and streaks. The calendar revolves around the two largest U.S. hematology and oncology conferences: The American Society of Clinical Oncologists (ASCO) meetings in June, and the American Society of Hematology (ASH) meetings in December.That is where researchers and drug companies present their most important study results. Starting as early as
What Happens After My Stem Cell Transplant? To Use Maintenance Or Not Use Maintenance – That Is The Question!
Yesterday I shared how--after almost four years--I have decided to go ahead with a stem cell transplant.The decision wasn't as difficult as I made it seem. Its time. But I wanted to detail how and why I made my decision to help some of you who may find yourself in a similar situation in the
Here is an interesting article I found in the Cornell Daily Sun this morning. Interesting because it is combines basics with a very insightful look at a promising clinical trial featuring pomalidomide:Weill Develops Alternative Cancer TreatmentJanuary 26, 2011 By Maria Minsker For patients suffering from cancer, learning their body is resistant to traditional therapy can
Fellow blogger, caregiver and regular reader, Lori Puente, forwarded me a link to this article about a 10 year multiple myeloma survivor a few weeks ago. I saved it to pass along when I got a chance: Survivor’s Stories: Dr. Mel - Dedicated to tomorrow’s outlook This year, I'm marking my tenth anniversary with multiple myeloma.
Late last month I received this e-mail comment from fellow patient Jack Searight, in response to my four part series of articles following my visit with multiple myeloma specialist Dr. James Berenson in Los Angeles. Jack apparently had trouble getting Blogger to accept his comment. From my experience, Jack's difficulties are not unusual. I think
I have received a number of calls and e-mails recently from patients who's multiple myeloma has become active again while using Revlimid, Velcade, or both. Here is a short, hopeful response I found addressing this on the Multiple Myeloma Research Foundation (MMRF) Website:Treatment Options for Relapsed or Refractory Patients Failing Revlimid and Velcade: Q&A with